Drug intelligence / Profile preview

LPT-352

Development stage: Preclinical
Lead developer: LitePharmTech
Modality: Small Molecules
Administration: Ophthalmic

Overview

LPT-352 is an investigational ophthalmic solution under development by LitePharmTech. It is classified as an Improved Medical Device/Drug (IMD), a category often used for products that offer enhanced therapeutic properties or delivery compared to existing treatments. Currently in the preclinical stage, LPT-352 is being evaluated for ophthalmic applications, though its specific active pharmaceutical ingredient and molecular mechanism of action have not been disclosed by the developer.

Beyond the preview

Go deeper on LPT-352.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LPT-352.

Explore the full profile